Elafibranor Alternatives Compared
Elafibranor | Ocaliva | Ursodiol |
|
---|
Elafibranor | Ocaliva (obeticholic acid) | Ursodiol |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Primary Biliary Cholangitis . elafibranor may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Primary Biliary Cholangitis . Ocaliva may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Primary Biliary Cholangitis , Nonalcoholic Steatohepatitis, Gallbladder Disease. ursodiol may also be used for purposes not listed in this medication guide. |
Related suggestions Primary Biliary Cholangitis
|
|||||||||||||||
More about Elafibranor | More about Ocaliva (obeticholic acid) | More about Ursodiol | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Be the first to share your experience with this drug. |
Ocaliva has an average rating of 7.0 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
Ursodiol has an average rating of 8.1 out of 10 from a total of 31 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 11% reported a negative effect. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
See also: elafibranor side effects in more detail. |
See also: Ocaliva side effects in more detail. |
See also: ursodiol side effects in more detail. |
||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
Lower cost generic |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ocaliva prices |
View all ursodiol prices |
||||||||||||||||
Dosage Forms Available | ||||||||||||||||||
N/A |
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
Iqirvo |
N/A |
Actigall, Reltone, Urso, Urso Forte | ||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
92.2 hours |
N/A |
100 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Summary unavailable. |
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 237 drugs are known to interact with elafibranor:
|
A total of 63 drugs are known to interact with Ocaliva:
|
A total of 4 drugs are known to interact with ursodiol:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
June 10, 2024 |
May 27, 2016 |
December 31, 1987 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.